| Title : Oral Administration of Lactobacillus gasseri and Lacticaseibacillus rhamnosus Ameliorates Amyloid Beta (Abeta)-Induced Cognitive Impairment by Improving Synaptic Function Through Regulation of TLR4\/Akt Pathway - Choi_2025_Antioxidants.(Basel)_14_ |
| Author(s) : Choi HJ , Lee HL , Kim IY , Ju YH , Heo YM , Na HR , Lee JY , Choi SI , Heo HJ |
| Ref : Antioxidants (Basel) , 14 : , 2025 |
| Abstract : |
| PubMedSearch : Choi_2025_Antioxidants.(Basel)_14_ |
| PubMedID: 40002326 |
| Title : Oral Administration of Lactobacillus gasseri and Lacticaseibacillus rhamnosus Ameliorates Amyloid Beta (Abeta)-Induced Cognitive Impairment by Improving Synaptic Function Through Regulation of TLR4\/Akt Pathway - Choi_2025_Antioxidants.(Basel)_14_ |
| Author(s) : Choi HJ , Lee HL , Kim IY , Ju YH , Heo YM , Na HR , Lee JY , Choi SI , Heo HJ |
| Ref : Antioxidants (Basel) , 14 : , 2025 |
| Abstract : |
| PubMedSearch : Choi_2025_Antioxidants.(Basel)_14_ |
| PubMedID: 40002326 |
| Title : Oral Administration of Lactobacillus gasseri and Lacticaseibacillus rhamnosus Ameliorates Amyloid Beta (Abeta)-Induced Cognitive Impairment by Improving Synaptic Function Through Regulation of TLR4\/Akt Pathway - Choi_2025_Antioxidants.(Basel)_14_ |
| Author(s) : Choi HJ , Lee HL , Kim IY , Ju YH , Heo YM , Na HR , Lee JY , Choi SI , Heo HJ |
| Ref : Antioxidants (Basel) , 14 : , 2025 |
| Abstract : |
| PubMedSearch : Choi_2025_Antioxidants.(Basel)_14_ |
| PubMedID: 40002326 |
| Title : Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease - Park_2019_Sci.Adv_5_eaav0316 |
| Author(s) : Park JH , Ju YH , Choi JW , Song HJ , Jang BK , Woo J , Chun H , Kim HJ , Shin SJ , Yarishkin O , Jo S , Park M , Yeon SK , Kim S , Kim J , Nam MH , Londhe AM , Cho SJ , Cho S , Lee C , Hwang SY , Kim SW , Oh SJ , Cho J , Pae AN , Lee CJ , Park KD |
| Ref : Sci Adv , 5 :eaav0316 , 2019 |
| Abstract : |
| PubMedSearch : Park_2019_Sci.Adv_5_eaav0316 |
| PubMedID: 30906861 |
| Title : Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease - Park_2019_Sci.Adv_5_eaav0316 |
| Author(s) : Park JH , Ju YH , Choi JW , Song HJ , Jang BK , Woo J , Chun H , Kim HJ , Shin SJ , Yarishkin O , Jo S , Park M , Yeon SK , Kim S , Kim J , Nam MH , Londhe AM , Cho SJ , Cho S , Lee C , Hwang SY , Kim SW , Oh SJ , Cho J , Pae AN , Lee CJ , Park KD |
| Ref : Sci Adv , 5 :eaav0316 , 2019 |
| Abstract : |
| PubMedSearch : Park_2019_Sci.Adv_5_eaav0316 |
| PubMedID: 30906861 |
| Title : Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease - Park_2019_Sci.Adv_5_eaav0316 |
| Author(s) : Park JH , Ju YH , Choi JW , Song HJ , Jang BK , Woo J , Chun H , Kim HJ , Shin SJ , Yarishkin O , Jo S , Park M , Yeon SK , Kim S , Kim J , Nam MH , Londhe AM , Cho SJ , Cho S , Lee C , Hwang SY , Kim SW , Oh SJ , Cho J , Pae AN , Lee CJ , Park KD |
| Ref : Sci Adv , 5 :eaav0316 , 2019 |
| Abstract : |
| PubMedSearch : Park_2019_Sci.Adv_5_eaav0316 |
| PubMedID: 30906861 |